StockData

CervoMed vs Genelux

CRVO and GNLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and GNLX compare

Genelux is the larger company, worth 4.0 times as much as CervoMed ($90.5M against $22.7M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOGNLX
Size and price
Market cap$22.7M$90.5M
Share price$1.50$2.00
Change, 1 year−80.5%−62.4%
Change, 5 years−94.9%–
Beta (5Y)3.410.73
Employees15–
StockData Score
Total score55
Valuation score1 (better)0
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/S68.5×–
P/B1.0× (better)5.6×
FCF yield–−31.7%
Growth
Revenue growth (TTM)−95.7%–
Profitability
Operating margin−9407%–
Net margin−9161%–
Return on equity−108% (better)−178%
Financial health
Debt / equity0.000.00
Current ratio–2.39
Altman Z-score−5.50 (better)−14.83
Piotroski F-score11
Dividends and buybacks
Buyback yield–−20.8%
Shareholder yield0.00% (better)−20.8%
Ownership
Held by institutions11.6%21.7%
Held by insiders36.9%7.7%
Insider net buying, 12 months$3.0M (better)−$341K
Short interest, % of float12.7%10.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.